Business
Galectin Therapeutics Appoints Seasoned Biopharmaceutical Executive Pol F. Boudes, M.D. as Chief Medical Officer
Appointment of industry veteran reflects growing confidence in clinical development program for NASH Cirrhosis NORCROSS, Ga., Feb. 20, 2020 (GLOBE NEWSWIRE)
About this update from Galectin Therapeutics Inc.
[{"type":"text","content":"Appointment of industry veteran reflects growing confidence in clinical development program for NASH Cirrhosis\nNORCROSS, Ga., Feb. 20, 2020 (GLOBE NEWSWIRE) -- Galectin Therapeutics Inc. (NASDAQ:GALT), a leader in the field of NASH therapeutics, today announced the appointment of Pol F. Boudes, M.D. to the position of Chief Medical Officer. In this position, Dr. Boudes will oversee Galectin’s global advanced clinical development of belapectin (GR-MD-02) for NASH cirrhosis, as well as all other company clinical and scientific initiatives. Dr. Boudes brings more than 25 years of experience in clinical drug development in liver-related diseases -- most recently NASH -- and immunology, endocrine, metabolic and orphan diseases. \n\n \n \n \n \n \n \n \n \n \n \n \n Pol F. Boudes, M.D., Chief Medical Officer at Galectin Therapeutics\n \n \n \n \n \n \n \n \n\n “Strengthening our executive team is a key development for the company, enhancing our future growth trajectory as we near launch of our NASH-RX trial, an adaptively-designed Phase 3 trial in NASH cirrhosis,” said Dr. Harold H. Shlevin, CEO. “Dr. Boudes’s diverse background in drug development, especially his experience in NASH and in related diseases, adds an important layer of expertise in relevant therapeutic areas and bolsters our ability to advance the development of our galectin-3 product assets. We are excited to have him join our team.” Chairman of Galectin, Mr. Richard E. Uihlein said, “On behalf of myself and the entire board, we are extremely pleased to have such a high quality Chief Medical Officer joining our excellent team. We believe the hiring of Dr. Boudes demonstrates the continued optimism and focus we collectively have on advancing our drug candidate through the planned upcoming trial in an effective and efficient manner.” Dr. Boudes will report directly to Galectin’s CEO Harold Shlevin, PhD. and serve as a member of the company’s executive management team. \"I am very excited to join at such an important moment,” said Dr. Boudes. “The team at Galectin has done a remarkable job to advance the belapectin program with the planned initiation of a well-designed and innovative late-stage adaptive study. The drug candidate is anchored on a well-understood mechanism of action, and its effect in preventing the development of esophageal varices, if confirmed, could co...